Abstract
Introduction
Cancer therapies make up one of the fastest-growing therapeutic areas in the
global pharmaceutical market. IMS Health expects global sales of cancer
therapies to more than double in just four years, exceeding $65 billion in
2010. Not surprisingly, the pharmaceutical industry is eager to tap the
potential of this market. A critical factor in this growth, in both the United
States and the European market, is the ever-evolving reimbursement
environment-and the political trends that infl uence it.
Get the Answers You Need to Shape Your Strategy
- Oncology drugs form one of the largest therapeutic areas of the global
pharmaceutical market, with worldwide sales of almost $30 billion in 2006.
What factors account for the success of this fast-growing market? How is
the pharmaceutical industry responding to this growth?
- Increasingly restrictive reimbursement policies will continue to impose
strict cost controls on cancer therapies. How will the U.S. Medicare system
manage its funding policies? What changes are in store for cancer therapy
reimbursements by commercial insurers? How will the new funding program in
France affect its high rate of spending on cancer drugs? How will reform
measures in Germany affect its reference pricing system. What changes are
included in Italy' s new national health system? Will the U.K.' s new Cancer
Reform Strategy affect spending on cancer drugs?
- The global market for oncology drugs will continue to grow vigorously in
the coming years. Are the industry' s pricing strategies expected to change
in the worldwide market? What strategies will pharmaceutical companies
undertake to expedite the launch of new drugs in Europe?
Scope
- The fi ght against cancer is one of the highest healthcare priorities
in all advanced economies: government funding systems; worldwide public
and private reimbursement programs; payment policies for innovative cancer
therapies.
- U.S. and European government insurance systems are all under pressure
to rein in healthcare costs: reimbursement for cancer therapies is a
target for cost cutting; offi ce-based cancer treatments create payment
challenges for physicians; pharmaceutical companies need to establish an
infrastructure for conducting price negotiations with payers.
- Health technology assessment (HTA) now infl uences a wide span of
product life cycles: earlystage R&D affected by the demands of HTA;
evidence of clinical effectiveness needed to defend a drug against the threat
of price cuts.
- Illustrated fi gures: Percentages of private and Medicare plans
that place restrictions on the use of select targeted cancer therapies.
| 
View Cart
